Proxy Blog

Bristol-Myers Squibb Company 

April 16, 2021

The annual proxy for this pharmaceutical company had the following proposals: 

  1. Proforma proposals on directors, appointment of auditors, and “say-on-pay” advisory vote 
  2. Board proposals on stock plan and lowering threshold for special meetings 
  3. Shareholder proposals on independent chairman, written consent, and lowering threshold for special meeting 

Magni voted as follows: 

  1. For and against proforma proposals.
    For directors – The disclosures meet the criteria in Magni’s policy on election of directors
    -For auditors – The company meets the criteria in Magni’s policy on auditor ratification.
    -Against advisory vote – The disclosures in the proxy did not meet the criteria in Magni’s policy on the advisory vote. 
  2. For board proposals.
    Stock purchase plan – Per Magni policy, Magni votes in favor of many of these proposals.
    -Lowering the threshold for special meetings – Per the Magni position paper, Magni routinely votes in favor of these proposals. 
  3. For and against shareholder proposals. 
    For independent chairman – Magni wrote a position paper regarding shareholder proposals for independent chairman.
    -Against written consent – Per the Magni position paper, Magni routinely votes against written consent proposals.
    -For lowering the threshold for special meetings – Per the Magni position paper, Magni routinely votes in favor of these proposals.